PMID- 21496941
OWN - NLM
STAT- MEDLINE
DCOM- 20110908
LR  - 20191210
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 72
IP  - 3
DP  - 2011 Jun
TI  - The search for improved systemic therapy of non-small cell lung cancer--what are 
      today's options?
PG  - 265-70
LID - 10.1016/j.lungcan.2011.02.020 [doi]
AB  - Although stage IV non small cell lung cancer (NSCLC) remains an incurable disease 
      and drug resistance ultimately develops, important steps forward have been made 
      within the last few years. The number of new active agents is rapidly increasing 
      and the area of personalized medicine has definitively arrived. Treatment choices 
      are starting to be made upon tumour characteristics, and more effective and 
      better tolerated agents are now available. In the molecular era we are facing 
      many new challenges: The availability of sufficient tissue, which is often not 
      easily accessible in a tumour arising from an internal organ, sensitivity and 
      specificity of biomarker testing, heterogeneity of marker profiles between 
      primary tumour and metastases or even within a single tumour mass, application 
      and reproducibility of the correct biomarker test method and the differentiation 
      of the predictive vs. the prognostic value of biomarkers. Unfortunately, the 
      development of new targeted agents frequently continues to be performed in 
      unselected patient populations, lacking the early identification of relevant 
      predictive molecular biomarkers. Consequently, thousands of patients are enrolled 
      into clinical trials with a low probability of success. This overview will focus 
      on the most recent new systemic treatment options in NSCLC, including the role of 
      pemetrexed, bevacizumab, cetuximab, maintenance therapy and tyrosine kinase 
      inhibitors in patients with an activating epidermal growth factor receptor 
      mutation. In addition, emerging treatment strategies will be described.
CI  - Copyright (c) 2011 Elsevier Ireland Ltd. All rights reserved.
FAU - Fruh, M
AU  - Fruh M
AD  - Department of Oncology/Hematology, Rorschacherstrasse 95, Kantonsspital St. 
      Gallen, 9007 St. Gallen, Switzerland. martin.frueh@kssg.ch
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20110414
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biomarkers, Pharmacological)
RN  - 0 (Glutamates)
RN  - 0 (Quinazolines)
RN  - 0 (Quinolines)
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 41UD74L59M (Afatinib)
RN  - 5Z93L87A1R (Guanine)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - JJH94R3PWB (neratinib)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Afatinib
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bevacizumab
MH  - Biomarkers, Pharmacological/metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology/physiopathology
MH  - Cetuximab
MH  - Clinical Trials as Topic
MH  - Glutamates/therapeutic use
MH  - Guanine/analogs & derivatives/therapeutic use
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/pathology/physiopathology
MH  - Pemetrexed
MH  - Precision Medicine
MH  - Protein-Tyrosine Kinases/antagonists & inhibitors
MH  - Quinazolines/pharmacology/therapeutic use
MH  - Quinolines/pharmacology/therapeutic use
EDAT- 2011/04/19 06:00
MHDA- 2011/09/09 06:00
CRDT- 2011/04/19 06:00
PHST- 2010/12/03 00:00 [received]
PHST- 2011/02/08 00:00 [revised]
PHST- 2011/02/27 00:00 [accepted]
PHST- 2011/04/19 06:00 [entrez]
PHST- 2011/04/19 06:00 [pubmed]
PHST- 2011/09/09 06:00 [medline]
AID - S0169-5002(11)00158-9 [pii]
AID - 10.1016/j.lungcan.2011.02.020 [doi]
PST - ppublish
SO  - Lung Cancer. 2011 Jun;72(3):265-70. doi: 10.1016/j.lungcan.2011.02.020. Epub 2011 
      Apr 14.